1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bora Pharmaceuticals Co., Ltd.

Bora Pharmaceuticals Co., Ltd.

6472.TW
Bora Pharmaceuticals Co., Ltd.TW flagTaiwan Stock Exchange
422.00
TWD
-3.50
- -
53.75BMarket Cap
Bora Pharmaceuticals Co., Ltd.
6472.TW
(Taiwan Stock Exchange)

Recent

price

422.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.6
1.47
2.61
2.74
3.28
3.89
13.76
14.25
15.66
52.46
89.62
117.95
142.66
- -
153.02
Revenue per Share
-3.46
0.06
0.2
0.39
0.28
0.15
4.44
2.84
5.03
8.03
11.89
25.17
31.54
- -
23.99
Basic EPS, GAAP
-3.25
-6.85
-0.01
-0.22
-0.35
0.07
1.31
-4.35
0.22
9.35
15.46
26.44
2.4
- -
28.14
Free Cash Flow per Basic Share
- -
- -
- -
0.13
0.16
0.23
0.13
0.82
0.72
1.18
2.04
5.14
10.09
- -
- -
Dividend per Share
4.46
3.07
2.88
3.02
3.11
3.16
7.5
6.6
12.3
21.46
26.18
44.76
60.54
- -
69.23
Book Value per Share
4.47
4.99
5.29
5.37
5.46
6.86
13.22
15.24
21.41
31.92
25.56
50.59
60.45
- -
90.36
Tangible Book Value per Share
5
63
84
87
86
92
100
107
115
93
117
120
122
- -
124
Basic Weighted Avg Shares
46
93
218
238
283
358
1,372
1,529
1,800
4,900
10,494
14,200
17,427
19,014
19,014
Sales/Revenue/Turnover
-36.28
2.15
11.75
7.97
10.79
5.2
13.65
22.55
12.56
21.35
18.32
36.97
21.28
17.33
17.33
Operating Margin (%)
1
3
15
16
20
21
111
120
141
210
325
606
1,026
1,087
1,087
Depreciation Expense
-17
4
17
34
25
14
443
305
578
750
1,392
3,030
3,853
2,981
2,981
Net Income, GAAP
- -
- -
17.76
4.14
11.31
13.75
8.61
6.25
2.85
26.78
23.83
24.41
19.25
15.72
15.72
Effective Tax Rate (%)
-36.1
4.18
7.62
14.16
8.67
3.92
32.27
19.95
32.14
15.3
13.26
21.34
22.11
15.68
15.68
Profit Margin (%)
21
125
83
319
244
393
639
689
340
951
1,745
2,375
9,569
6,017
6,017
Working Capital
- -
220
416
290
199
182
471
1,109
1,483
1,334
4,634
3,487
15,070
12,505
12,505
LT Debt
22
317
446
468
474
632
1,321
1,654
2,465
3,153
5,140
11,766
14,923
17,472
17,472
Total Equity
- -
- -
2.82
2.07
3.57
2.06
12.44
12.93
5.19
14.19
15.91
25.81
11.48
7.89
7.89
Return on Invested Capital (%)
- -
- -
3.63
6
5.18
3.03
49.42
18.46
18.66
18.51
18.9
25.6
19.9
11.58
11.58
Return on Capital (%)
- -
3.61
7.64
13.41
9.26
5.01
85.23
41.9
54.54
43.88
54.91
71.69
60.28
37.27
37.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
3,648
6,887
5,723
LT Borrowings
13,370
11,957
11,796
LT Finance Leases
740
724
709
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
124
124
127
Market Capitalization
85,674
85,737
60,637

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
17,783
18,275
19,338
Cash, Cash Equivalents & STI
4,376
4,472
5,137
Accounts Receivable, Net
7,645
8,079
8,790
Inventories
3,225
3,220
3,410
Total Current Liabilities
12,273
14,005
13,321
Payables & Accruals
- -
- -
- -
ST Debt
3,648
6,887
5,723
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
48.16%
52.75%
17.08%
Free Cash Flow
580.63%
896.65%
1,093.5%
Net Income, GAAP
328.5%
47.5%
-22.61%
Sales/Revenue/Turnover
71.18%
70.72%
9.11%
Total Cash Common Dividend
103.83%
85.06%
17.53%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
4,781
3,139
3,075
3,206
14,200
2024
2,857
4,417
5,027
5,746
17,427
2025
4,480
4,868
4,806
4,861
19,014

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
8.74
5.74
6.07
- -
25.17
2024
5.9
8.97
13.92
- -
31.54
2025
11.29
4.96
5.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5.14
2024
- -
- -
- -
- -
10.09
2025
- -
- -
- -
- -
- -
Similar Companies
Huakang Biomedical Holdings Company Limited (8622.HK)
Brooks Laboratories Limited (BROOKS.NS)
Taro Pharmaceutical Industries Ltd. (TARO)
Lasa Supergenerics Limited (LASA.NS)
BGM Group Ltd. (BGM)
Auxly Cannabis Group Inc. (CBWTF)
Business
Bora Pharmaceuticals Co., Ltd. engages globally in the research, development, production, distribution, and sale of diverse pharmaceutical products. The company operates through distinct divisions including its Commercial Sales arm, the Contract Development and Manufacturing Organization (CDMO) segment, and various other business ventures. It produces and markets a broad portfolio of prescription, over-the-counter, and specialized branded medications, alongside generic drugs. Furthermore, Bora offers comprehensive contract development and manufacturing solutions, encompassing pharmaceutical formulation, clinical and commercial scale production, advanced packaging with serialization, analytical and microbiological testing, and regulatory compliance support. The company has strategically expanded its footprint, notably through the 2024 acquisition of Upsher-Smith Laboratories, bolstering its U.S. market presence and generic drug capabilities. This was further enhanced by the October 2024 acquisition of Pyros Pharmaceuticals, which expanded its focus on rare disease treatments, including the launch of VIGAFYDE™ for infantile spasms. Bora has also made a significant investment in Tanvex Biopharma, combining biomanufacturing facilities to establish a robust global platform for biologics CDMO services, and acquired a sterile injectable manufacturing facility in Baltimore, Maryland, to boost fill/finish capabilities for large molecules. Additionally, it provides health supplements and skincare products. Its distribution network reaches clinics, pharmacies, and drugstores directly, while also supplying medical centers and hospitals through distributors across numerous international markets. Bora Pharmaceuticals Co., Ltd. was established in Taipei City, Taiwan, in 2007.